IPO Premiums
IPO calendar
SPListed

Senores Pharmaceuticals Limited

Bookbuilding IPO · NSE, BSE

Price band
₹372 - ₹391
Lot size
38 shares
Issue amount
₹582.11 cr
Total subscription
97.25×
Current price₹1,253.6
Listing price ₹600
Watch live price ↗
Opens
20 Dec 2024
Closes
24 Dec 2024
Allotment
26 Dec 2024
Listing
30 Dec 2024

Offer at a glance

Issue overview

Issue size
1,48,87,723 shares
Face value
₹10 per share
Minimum investment
₹14,136
Fresh issue
₹500 cr
Offer for sale
₹82.11 cr
Registrar
Link Intime India Private Limited
Listing exchange
NSE, BSE
Maximum investment
₹14,858
Issue type
Bookbuilding IPO
Shares before issue
3,32,65,865
Shares after issue
4,60,53,588

Lot sizes

CategoryLotsSharesAmount
Retail138₹14,858
sHNI14532₹2,08,012
bHNI682,584₹10,10,344

Share reservation

QIB54.05%
HNI27.02%
RETAIL18.02%
Employee0.91%

Subscription & GMP

Subscription by category

Total subscribed97.25×

Missing multiples are calculated from bids and offered shares when available.

QIBs 97.84×
HNIs100.54×
HNIs 10+ 95.25×
HNIs 2+ 111.96×
Retail 94.45×
Employees 20.21×

GMP history

014228414 Nov: ₹284
14 Nov₹28414 Nov

Application-wise demand

CategoryReserved applicationsApplied applications
HNIs (10L+) 2,64453,198
HNIs(2-10L)1,3221,42,233
Retail38,98230,76,031
Employee029,405

Subscription demand

Amounts in ₹ crore. HNI subcategories are included in the NII total.

CategoryOfferedDemand
NIB86.888,734.89

Financial performance

Company financials

In Crores · Reported periods may include interim results.

Revenue & profit In Crores
0100200300Mar-22 · Revenue: 15Mar-22 · Profit after tax: 1Mar-22Mar-23 · Revenue: 39Mar-23 · Profit after tax: 8Mar-23 Mar-24 · Revenue: 217Mar-24 · Profit after tax: 33Mar-24 Sep-24 · Revenue: 183Sep-24 · Profit after tax: 24Sep-24
RevenueProfit after tax

Key performance indicators

MetricSep-24 Mar-24 Mar-23
EPS7.213.678.87
ROE8.6923.620.55
ROCE7.5911.7318.56
RONW8.6923.620.55
PRE IPO039.770
POST IPO28.2100

Values and labels as reported in the issue data.

Company information

Company profile

Senores Pharmaceuticals Limited, incorporated on December 26, 2017, is an Ahmedabad-based pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded generic medicines for both domestic and global markets. Its diversified product portfolio spans key therapeutic areas, including gastrointestinal, cardiovascular, respiratory, pain management, and anti-infective segments. Driven by strong R&D capabilities, the company emphasizes innovation, cost-effective product development, and strict regulatory compliance. Senores operates through a robust distribution network supported by subsidiaries such as Ratnatris Pharmaceuticals Private Limited and Havix Group, Inc. (Aavis Pharmaceuticals). It serves customers across major international markets, including the US, Europe, and other emerging regions.

Strengths

  • Global Market Presence: Strong footprint across regulated and semi-regulated markets ensures diversified revenue and reduced geographical dependence.
  • Robust R&D & Manufacturing: Advanced R&D capabilities enable development of complex generics while adhering to strict global regulatory standards for quality.
  • Strategic Partnerships: Long-term relationships with major clients, suppliers, and distributors support steady growth and consistent revenue visibility.

Risk factors

  • Regulatory Challenges: Delays or denials in product approvals may hinder new launches and limit growth in key markets.
  • Raw Material Volatility: Dependence on external API and raw material suppliers exposes the company to price fluctuations and supply disruptions.
  • Intense Competition: A highly competitive pharma landscape may pressure pricing and reduce profit margins.

Promoters

Swapnil Jatinbhai Shah

Ashokkumar Vijaysinh Barot

Registrar & documents

Lead manager

Equirus Capital Private Limited, Ambit Private Limited, Nuvama Wealth Management Limited

Registered office

1101 to 1103, 11th floor,, South Tower, ONE 42 oppositeJayantilal Park, Ambali Bopal Road, Ahmedabad,-380054

+91-79-29999857

[email protected]Company website ↗

Frequently Asked Questions

What is Senores Pharmaceuticals IPO GMP today?

As of today, Senores Pharmaceuticals IPO Grey Market Premium (GMP) is reported at +₹284 per share. Based on the upper price band of ₹391, the estimated listing price is ₹675 (+72.6% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.

What is the lot size and minimum investment for Senores Pharmaceuticals IPO?

The minimum bid lot size for Senores Pharmaceuticals IPO is 38 shares. At the cut-off price of ₹391 per share, retail investors need a minimum application amount of ₹14,858 per lot. Retail applicants can apply for a maximum of 13 lots (up to ₹2,00,000).

When will Senores Pharmaceuticals IPO allotment status be announced?

The allotment status for Senores Pharmaceuticals IPO is scheduled to be finalized on 26 Dec 2024. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Link Intime India Private Limited's official portal or via BSE/NSE allotment portals.

How can I check Senores Pharmaceuticals IPO allotment status online by PAN?

To check Senores Pharmaceuticals IPO allotment status: 1) Visit the registrar portal (Link Intime India Private Limited) or the BSE IPO allotment page. 2) Select 'Senores Pharmaceuticals Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.

Explore More IPO Analysis & Live Tools

Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.

Regulatory Disclaimer: Grey Market Premium (GMP) is an unofficial, unregulated indicator of market sentiment and does not represent a stock exchange transaction, guarantee, or investment advice. IPO Premiums is an informational and research portal and is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before applying for any IPO.